European Medicines Agency targets GPs


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The European Medicines Agency (EMA) has announced a new partnership aimed at strengthening the agency’s interaction with general practitioners (GPs).

In a statement, the EMA announced that it will be working with the European Union of General Practitioners (UEMO), the European section of the World Organization of Family Doctors (WONCA) and the European Forum for Primary Care (EFPC).

While the EMA already has a framework of interaction with healthcare professionals including physicians, pharmacists, and nurses, interactions with GPs and feedback from primary care are currently limited.

It is hoped that the new working relationship will provide the EMA with a better understanding of how medicines are being used in real life and the potential impact of specific regulatory actions on patient care.

The statement sets out an action plan to guide the EMA, UEMO, the EFPC and WONCA in their joint work. Specific areas of collaboration include involving GPs and family physicians in EMA evaluation activities, developing communication activities relevant to GPs and family physicians, as well as exploring options for further collaboration with existing research networks in primary care, with a focus on generating real-world evidence. The action plan also identifies opportunities for cooperation in regulatory science training.